Key features and details
- PerCP/Cy5.5® Mouse monoclonal [VU-1D9] to EpCAM
- Reacts with: Human
- Conjugation: PerCP/Cy5.5®. Ex: 482nm, Em: 690nm
- Isotype: IgG1
Product namePerCP/Cy5.5® Anti-EpCAM antibody [VU-1D9]
See all EpCAM primary antibodies
DescriptionPerCP/Cy5.5® Mouse monoclonal [VU-1D9] to EpCAM
ConjugationPerCP/Cy5.5®. Ex: 482nm, Em: 690nm
Specificityab157319 recognizes an epitope within EGF-like domain I of EpCAM, a marker of epithelial lineages. This antibody strongly stains various normal epithelial cells and carcinomas.
Species reactivityReacts with: Human
Small cell lung carcinoma cell line H69.
- Recombinant Human EpCAM protein (ab131790) can be used as a positive control in WB. Colon epithelium
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferpH: 7.4
Preservative: 0.1% Sodium azide
Constituents: 99% PBS, 0.2% BSA
BSA is high-grade, protease free.
Concentration information loading...
Purification notesab157319 is conjugated with tandem dye PerCP-Cy™5.5 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- FITC Anti-EpCAM antibody [VU-1D9] (ab112067)
- PE Anti-EpCAM antibody [VU-1D9] (ab112068)
- Anti-EpCAM antibody [VU-1D9] (ab187372)
- Anti-EpCAM antibody [VU-1D9] - BSA and Azide free (ab212579)
- Alexa Fluor® 647 Anti-EpCAM antibody [VU-1D9] (ab239273)
- APC Anti-EpCAM antibody [VU-1D9] (ab239288)
- Biotin Anti-EpCAM antibody [VU-1D9] (ab79079)
FunctionMay act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
Tissue specificityHighly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.
Involvement in diseaseDefects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
Sequence similaritiesBelongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain.
modificationsHyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.
Cellular localizationLateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction.
- Information by UniProt
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
ab157319 has been referenced in 2 publications.
- Pedrol E et al. Optofluidic device for the quantification of circulating tumor cells in breast cancer. Sci Rep 7:3677 (2017). IHC-P ; Mouse . PubMed: 28623262
- Holton AB et al. Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. PLoS One 12:e0169797 (2017). PubMed: 28085924